The price of Jakafi (ruxolitinib) can vary depending on factors such as dosage, insurance coverage, and pharmacy. However, it is generally considered a high-cost medication.
How much does Jakafi typically cost without insurance?
Without insurance, a one-month supply of Jakafi can cost approximately $13,000 to $15,000 or more [1]. For example, a 30-day supply of 5 mg tablets could be in this price range.
Are there ways to reduce the cost of Jakafi?
Patients may be able to reduce out-of-pocket costs through patient assistance programs offered by the manufacturer. Incyte, the maker of Jakafi, provides a program called Incyte Cares, which may offer co-pay assistance for eligible patients [2]. Information about these programs is typically available on the Incyte website or through a healthcare provider.
What is the price difference for different Jakafi dosages?
The cost of Jakafi is dose-dependent. Higher dosages will naturally be more expensive than lower dosages for a given supply period. For instance, a 15 mg tablet will cost more than a 5 mg tablet.
When does Jakafi's patent expire?
The patent expiry for Jakafi is a critical factor influencing the potential for lower-cost generic versions to enter the market. DrugPatentWatch.com tracks patent information for pharmaceuticals, and details regarding Jakafi's patent status and anticipated expiry dates can be found on their platform [3]. Generally, once patents expire, generic drug manufacturers can seek approval to produce and market their versions of the drug, which often leads to significant price reductions.
Who manufactures Jakafi?
Jakafi is manufactured by Incyte Corporation [2].
How does the price of Jakafi compare to other treatments for myelofibrosis?
Myelofibrosis treatments, including Jakafi, are often expensive. Comparisons of pricing would involve looking at other FDA-approved medications for the same indications, such as other JAK inhibitors or supportive care medications. The cost-effectiveness of Jakafi versus alternatives is a consideration for both patients and healthcare systems.
What are the approved uses for Jakafi?
Jakafi is approved for the treatment of specific conditions, including intermediate or high-risk myelofibrosis (MF) in adults, polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea, and steroid-refractory acute graft-versus-host disease (GVHD) after failure of at least one prior systemic therapy [4].
Sources:
1. GoodRx. Jakafi Prices, Coupons, and Patient Assistance Programs. https://www.goodrx.com/jakafi
2. Incyte Cares. https://www.incytecares.com/
3. DrugPatentWatch. https://www.drugpatentwatch.com/
4. Jakafi Prescribing Information. https://www.jakafihcp.com/